Reviva Pharmaceuticals Engages with Investors at Major Summit
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is gearing up to participate in a significant event that promises to illuminate their groundbreaking work within the pharmaceutical industry. As a leading late-stage biopharmaceutical company, Reviva focuses on developing innovative therapies aimed at addressing critical healthcare needs, particularly in the central nervous system (CNS), inflammatory, and cardiometabolic disease sectors.
Presentation Details for the Healthcare Summit
On a notable virtual platform, Laxminarayan Bhat, Ph.D., who serves as the President and CEO of Reviva, will host a webcast presentation at the upcoming Lytham Partners 2025 Investor Healthcare Summit. This event, which is set for January 13, 2025, at 12:30 p.m. ET, presents a valuable opportunity for investors and stakeholders to gain insights into the company’s advancements and objectives.
Accessing the Webcast
Individuals interested in tuning in to the presentation can easily access the webcast via the event's home page. The company is excited to share vital information about their pipeline and ongoing projects, which are crucial for advancing healthcare solutions.
Replay Availability
For those unable to attend the live session, a replay will also be available, ensuring that all interested parties can catch up on the discussion and key highlights presented during the summit.
Follow-Up Opportunities for Investors
After the summit, Reviva is committed to fostering connections with potential investors through personalized 1x1 meetings. Interested parties are encouraged to reach out to the Lytham representative for more information on arranging these discussions.
Understanding Reviva’s Mission
As a trailblazer in the biopharmaceutical space, Reviva is dedicated to the discovery and development of next-generation therapeutics aimed at addressing the unmet medical needs of patients. The company’s current pipeline includes significant drug candidates, such as brilaroxazine (RP5063) and RP1208, both of which are new chemical entities developed in-house. Each of these candidates reflects Reviva’s commitment to innovation and patient care.
Protecting Intellectual Property
Reviva has been proactive in securing the future of its groundbreaking therapies by obtaining composition of matter patents for brilaroxazine and RP1208 in key markets, including the United States and Europe. This commitment to protecting its intellectual property reinforces their strategy for long-term success and contribution to global health.
Corporate and Investor Relations Contact Information
For those seeking further information regarding Reviva Pharmaceuticals, the company can be contacted directly through:
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
Website: www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
Email: bmackle@lifesciadvisors.com
Frequently Asked Questions
What is Reviva Pharmaceuticals known for?
Reviva Pharmaceuticals develops therapies targeting unmet medical needs in CNS, inflammatory, and cardiometabolic diseases.
When is the webcast presentation?
The presentation by Dr. Laxminarayan Bhat is scheduled for January 13, 2025, at 12:30 p.m. ET.
How can I access the webcast?
The webcast can be accessed through the conference home page on the day of the presentation.
Will there be opportunities for one-on-one meetings?
Yes, Reviva offers 1x1 investor meetings after the event upon request.
What are the key drug candidates in Reviva's pipeline?
The key candidates currently include brilaroxazine (RP5063) and RP1208, both of which have received patent protection in several regions.
